SCHEMBL3015530

SCHEMBL3015530

COc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3cc(Br)ccc3OC)CC2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.40
DRD4 P21917 7/20 0.40
DRD3 P35462 7/20 0.40
GAA P10253 2/20 0.38
ALOX15 P16050 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
ALPL P05186 1/20 0.36
ALDH1A1 P00352 3/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
PPARG P37231 1/20 0.36
GFER P55789 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017679 0.93 DRD2 (0.39) DRD2DRD4DRD3GAAALOX15
SCHEMBL3014355 0.91 DRD2 (0.37) DRD2DRD4DRD3ALDH1A1LMNA
SCHEMBL3008649 0.91 ALDH1A1 (0.38) DRD2DRD4DRD3GAAALOX15
SCHEMBL3011978 0.90 ALDH1A1 (0.44) GAAKMT2AMEN1ALDH1A1LMNA
SCHEMBL3007655 0.90 DRD2 (0.45) DRD2DRD4DRD3GAAALOX15
SCHEMBL3018934 0.90 DRD2 (0.40) DRD2GAAADRA1DADRA1AADRA1B
SCHEMBL3017903 0.90 PKM (0.37) DRD2DRD4DRD3GAAALOX15
SCHEMBL3006435 0.90 MAPT (0.38) DRD2DRD4DRD3GAAALOX15
SCHEMBL3004621 0.89 DRD2 (0.41) DRD2DRD4DRD3GAAALOX15
SCHEMBL3013002 0.89 SMN1; SMN2 (0.38) DRD2DRD4DRD3GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DRD2 573/4885DRD4 1124/4885DRD3 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.